Form 4: Arrowhead Director Waddill Receives RSU Grant

Arrowhead Pharmaceuticals Director William D. Waddill was granted 7,819 restricted stock units, increasing his beneficial ownership to 64,930 shares.

Summary

• William D. Waddill, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 7,819 shares of common stock.
• The transaction occurred on December 16, 2025.
• These shares represent restricted stock units (RSUs) granted at a price of $0.
• The RSUs will vest in one installment on the first anniversary of the grant date, subject to Mr. Waddill's continued service.
• Following this transaction, Mr. Waddill beneficially owns a total of 64,930 shares of common stock.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates standard director compensation and aligns interests, but not a significant market-moving event.

Positives

• The grant of restricted stock units to Director William D. Waddill aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The increase in beneficial ownership demonstrates continued commitment from a key director.

Negatives

• No negative information is presented in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The 7,819 restricted stock units are expected to vest on December 16, 2026, contingent upon Mr. Waddill's continued service to Arrowhead Pharmaceuticals.

Industry Context

Granting restricted stock units to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across many public companies, to incentivize long-term commitment and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a director is a standard form of equity compensation, widely used by public companies, including those in the biotechnology sector, to attract and retain talent and align interests.
• The vesting schedule, typically over one to three years, is also common, with this specific grant vesting in one installment after one year, which is a common practice for director grants.

Related Party Transactions

• The transaction is a compensation grant to a director, which is a related party transaction but is standard and disclosed.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value.

Next Steps

• The restricted stock units will vest on December 16, 2026, assuming continued service by William D. Waddill.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, William D. Waddill, Director, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership